We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rare Infection in Transplant Recipients Linked to Donors

By LabMedica International staff writers
Posted on 01 Jun 2017
Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
Image: Mycoplasma hominis, the bacteria responsible for a rare infection in transplant recipients (Photo courtesy of the Mayo Clinic).
The way in which heart and lung transplant recipients acquired a specific species of bacteria, Mycoplasma hominis, had been previously undefined, and the bacterium was difficult to test for and detect. Originally, this bacterium was considered to reside exclusively in, and be a potential pathogen of the area of the reproductive and urinary organs.

M. hominis resists most antibiotics, and the three antibiotic treatment recommendations for these infections are neither standard for post-transplant recipient care nor are they standard in therapy regimens for surgical site infections. Heart and lung transplant recipient infection caused by M. hominis may present with, surgical site infection and mediastinitis, which is an inflammation of tissue in mid-chest.

Scientists at the Mayo Clinic investigated lung and heart-lung transplants between 1998 and July 2015 at the Mayo Clinic. Seven previously unreported cases of transplant recipients with M. hominis infection were discovered. In each case, pre-transplant sputum cultures had tested negative for M. hominis. A literature review since 1950 found 15 cases of M. hominis infection in lung, heart or heart-lung transplant recipients. The way the bacteria spread remained uncertain. Given its normal residence in the genitourinary tract, some speculated that infection arose from urinary catheter placement during the transplant surgery.

Bronchoalveolar lavage samples were submitted for detecting organisms commonly found in immunocompromised hosts undergoing clinically indicated bronchoscopy were tested for M. hominis DNA. DNA was extracted on the MagNA Pure LC instrument using the MagNA Pure total nucleic acid isolation kit. Common testing methods have proven insufficient in identifying the bacteria, but the use of polymerase chain reaction offered a more time-sensitive and specific test for the bacteria. With this method, the scientists were able to focus in on a certain portion of DNA and then create multiple copies to amplify the segment. Polymerase chain reaction detection reduces the time to detect M. hominis to a few hours, compared to the two to five days needed for a culture media test.

Mark E. Wylam, MD, the lead investigator said, “These findings could affect how we approach the evaluation of organ donors. If potential transmission of these harmful bacteria can be identified and addressed, the recipient will face a decreased risk of infection and its serious complications. This study shows us that surveillance of both donor and recipient are important in recognizing M. hominis and the infection it can cause.” The study was published in the May 2017 issue of the journal EbioMedicine.

New
Gold Member
Hybrid Pipette
SWITCH
Portable Electronic Pipette
Mini 96
Clinical Chemistry System
P780
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
GLOBE SCIENTIFIC, LLC